ReiThera News and Resources

ReiThera, in collaboration with the Sabin Vaccine Institute, has commenced a pivotal role in addressing the Marburg virus outbreak by manufacturing and shipping around 700 investigational vaccine doses to Rwanda. This shipment supports a Phase 2 rapid response clinical trial

ReiThera, a CDMO company dedicated to technology and process development and GMP manufacturing has initiated a Phase 2 clinical trial in Uganda for a vaccine targeting the Sudan ebolavirus, marking a significant step in addressing life-threatening infectious diseases. The trial

ReiThera, a contract manufacturing organisation (CDMO), has announced the appointment of Stefano Colloca as its new Chief Executive Officer. The announcement was made on 6th July 2024. Stefano Colloca, a seasoned leader in viral vector technologies, co-founded and directed numerous